Figure 4From: Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting Change in the mean CNV size (μm) of reduced responders (black) and responders (white) at baseline (month 0) and after the first three consecutive injections (month 4), until the end of follow-up (month 6). Back to article page